Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type ... ( Patient Advocacy Partners For...)

HOME >> MEDICINE >> TECHNOLOGY

Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes

Date:1/19/2010

Patient Advocacy Partners Forge Collaboration to Fund Discovery of New Drugs that Target the Immune System

NEW YORK and MILAN, Italy, Jan. 19 /PRNewswire-USNewswire/ -- Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA -- a leading company in conducting early-stage discovery research programs for the life science industry -- to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).

Under the terms of the agreement, Axxam will screen its extensive chemical library to identify compounds that can target specific ion channels in the immune system. Ion channels are tiny pores on the surface of immune cells that control the influx of charged particles and allow the cells to become activated to perform their natural surveillance and protection functions. Recent studies have found that immune cells in MS and T1D contain high levels of a specific ion channel, Kv1.3, and that the hyperactivity of this channel contributes to the dysfunction of the immune system in MS and T1D. If the initial research is successful, Axxam will have identified compounds that modulate Kv1.3 ion channel activities, and these will be further developed by the company as potential therapies for MS and T1D.

The agreement with Axxam is the first of its kind between cross-disciplinary patient advocacy organizations and represents a new frontier in which groups such as JDRF and Fast Forward ally to lessen the risk of drug discovery and accelerate the development of new therapies that can impact m
'/>"/>

SOURCE Juvenile Diabetes Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
2. Juvenile Diabetes Research Foundation to Honor Duane DeSisto of Insulet Corporation and Senator Edward M. Kennedy at 27th Annual Hearts & Heroes Gala
3. Pediatric Researchers Find Possible Master Switch Gene in Juvenile Arthritis
4. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
5. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
6. JDRF Forms Partnership With Animas to Develop First-Generation Automated System for Managing Type 1 Diabetes
7. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
8. Single Dose of Proprietary Adult Stem Cells Regenerates Damaged Pancreas and Reduces Blood Glucose Levels in Diabetes
9. Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors
10. deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin
11. 183 New Medicines in Development for Diabetes

Post Your Comments:

(Date:6/18/2013)... SALT LAKE CITY , June 18, 2013 ... registry-based informatics products for healthcare and life sciences ... U.S. General Services Administration (GSA) IT Schedule 70 ... is now certified to provide innovative IT solutions ... levels. In accordance with this contract, Remedy has ...

(Date:6/18/2013)... 2013 Polymer Technology Systems, Inc. ... Group to integrate the CardioChek ® ... by health systems across the country. The CardioChek ... distributed through Hanson Medical Systems , offers ... LDL cholesterol, triglycerides, and glucose. (Logo: ...

(Date:6/17/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... filed a preliminary prospectus supplement to its effective shelf registration ... filing with securities regulatory authorities in each of the provinces ... public offering of its common shares to raise gross proceeds ... will also grant to the underwriters of the Offering an ...

Breaking Medicine Technology:Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2 Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3 Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3 Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2 Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3 Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4

[0] Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies [0] Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients [0] Valeant Pharmaceuticals Announces Public Offering Of Common Shares

... 28 Amira Pharmaceuticals, Inc. announced today that it ... a novel LPA1 antagonist, in normal, healthy subjects. ... exploring the therapeutic value of AM152, a potentially novel ... safety, pharmacodynamic (PD) and pharmacokinetic (PK) profile of this ...

... Millennium Research Group (MRG), the global authority ... latest orthopedics research data including information for multiple ... extremity devices. MRG orthopedic biomaterial reports ... and material, hyaluronic acid viscosupplementation treatments by number ...

Cached Medicine Technology:Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist 2 New Orthopedic Market Research Data Covering Multiple Geographies Released by Millennium Research Group 2

Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist New Orthopedic Market Research Data Covering Multiple Geographies Released by Millennium Research Group

(Date:6/18/2013)... NY (PRWEB) June 18, 2013 ... hip continue to move forward in a multidistrict litigation ... Liebhard LLP reports. According to court records, the ... 17th, at which time the Court also convened a ... technical issues pertinent to the Biomet hip replacement litigation. ...

(Date:6/18/2013)... Medical Center clinical researchers have launched an innovative ... evaluate the ability of a patient,s own stem ... peripheral arterial disease (PAD). , Led by ... University Hospitals Case Medical Center,s Harrington Heart & ... Western Reserve University School of Medicine, the clinical ...

(Date:6/18/2013)... DC (PRWEB) June 18, 2013 The ... Department of State and the U.S. President’s Emergency Plan ... anniversary and celebrate significant new milestones in the global ... State John Kerry announced that as of June 2013, ... to PEPFAR support. Since PEPFAR’s inception in 2003, ...

(Date:6/18/2013)... (PRWEB) June 18, 2013 Today, Zane ... Health Reimbursement Accounts . Zane Benefits, which provides comprehensive ... is the leader in defined contribution and ... Zane Benefits’ website, employees of a company who sets ... have questions about how Health Reimbursement Accounts work. Educating ...

(Date:6/18/2013)... York, N.Y., June 18, 2013 -- Lauren Sciences, ... novel V-Smart nanovesicle platform technology, announced today that ... in Drug Delivery with its V-Smart Platform, and ... report by MCD Group. , The ... of Start-ups and Emerging Companies ," features companies ...

Breaking Medicine News(10 mins):Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2 Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3 Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2 Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2 Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3 Health News:Zane Benefits Publishes New Information on Health Reimbursement Accounts 2

[0] Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation [0] UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation [0] One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS [0] Zane Benefits Publishes New Information on Health Reimbursement Accounts [0] Lauren Sciences independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in new report by MCD Group

... is pleased to announce,the latest release of TMS Enterprise and ... as requested by our customers., Features such as a ... and retire tasks are just a few of the timesaving ... retire tasks allows users to,remove or retire unnecessary tasks from ...

... Diabetes Federation (IDF) BRIDGES translational research grant program will ... for screenings for people at high-risk for getting type ... people to develop a healthy lifestyle. , The National ... Vinh City, Vietnam. Using diabetes risks questionnaires (1) , ...

... to $9.2 Million, CHENGDU, China, May 15 ... TYNP), a manufacturer and,supplier of modernized traditional Chinese ... results for its third quarter ended,March 31, 2008., ... increased 70.9% to approximately,$9.2 million compared to approximately ...

... Gerson Lehrman Group, the world,s,leading marketplace for ... community devoted to providing patients with the,medication information ... provides personalized iGuard Risk Ratings, iGuard Safety Alerts,and ... with other registered,users who also want to get ...

... Global Unified Worklist Supporting ... SEATTLE, May 15 Compressus, leaders in interoperability,of ... of,Seattle, announced today an agreement to implement a ... management systems.,The implementation, which will include eight SeaRad ...

... is a chief reason that,patients seek medical attention; ... Physicians must be able to determine which opioid,treatment ... To make clinicians aware of the importance ... Current Clinical Practice and The,Journal of Family Practice: ...

Four Rivers Software Systems Delivers TMS Enterprise 2008.3.4 International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions Compressus Announces Seattle Radiologists Interoperability Implementation Treat Your Patients' Pain Effectively

Length-9 (229 mm) Tapered retractor blades....

Pattie Tray...

... for the retraction of nerves, vessels, delicate ... brain retraction. Equalized brain retraction pressure. Decreased ... Range of blade sizes from 1/4" to ... material allows preferred contour. Used in conjunction ...

The Budde Halo Retractor Side Rail Support is designed for the adaptation and attachment of the Budde Halo Brain Retractor System to the operating room table when a conventional skull clamp is not us...

Medicine Products:

Greenberg Short Retractor Arm Pattie Tray Budde Retractor Blades Budde Halo Side Rail Support